ENCYSIVE PHARMACEUTICALS' APPLICATION FOR THELIN(TM) ACCEPTED FOR REVIEW BY EMEA

Encysive Pharmaceuticals (Nasdaq: ENCY) today announced that the European Agency for the Evaluation of Medicinal Products (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for Thelin(TM) (sitaxsentan) 100 mg as a once daily oral treatment for patients with pulmonary arterial hypertension (PAH). The MAA, submitted on July 28, 2005, has passed validation and is now under active review by the EMEA's Committee for Medicinal Products for Human Use.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-17-2005/0004090288&EDATE=)